Implantable Devices: Rule 8 and the Three Exceptions

1. Key takeaways

The classification of implantable devices in Argentina is determined by Rule 8 of Annex II of GMC 25/21: implantable devices and surgically invasive devices intended for long-term use (more than 30 days) fall into Class III, subject to three exceptions:

1. Devices placed in the teeth → Class II;
2. Devices in direct contact with the heart, the circulatory system or the central nervous system → Class IV;
3. Devices producing a biological effect or being wholly or mostly absorbed by the body → Class IV.

In day-to-day projects, the two-pronged definition is most often misread for partially implanted products — catheters, leads, sutures and meshes that cross a body surface but do not wholly reside inside the body. For these, the analysis is not whether the product looks like a classic implant, but whether it remains in place for at least 30 days after the procedure. A mesh that stays permanently and a temporary drainage device that is removed within days sit on opposite sides of the definition even though both are surgically introduced.

The legal definition of implant has two layers: products wholly introduced into the human body, or replacing an epithelial or ocular surface by medical intervention and remaining in place after the procedure; and products partially introduced into the human body by medical intervention and remaining in place for at least 30 days after the procedure. Both prongs must be checked, because a product can fail the first prong and still qualify under the second purely through its residence time.

2. Legal basis

The instruments below cover the classification rule itself, the transposition instrument, and the traceability regulation that adds a second layer of obligations for listed implantable devices.

3. Expert insights

Insight one: 30 days is the core dividing line for implant classification. A partially introduced product that remains in place for less than 30 days does not fall under the Class III baseline of Rule 8 and must instead be re-assessed under Rules 5–7 by invasive duration. How a company phrases the residence time in its instructions for use becomes a checkpoint for reviewers. The stated duration must be supportable by the clinical evidence, because a duration that shifts to escape Rule 8 is exactly the kind of inconsistency that triggers scrutiny of the whole file.

Insight two: the three exceptions place orthopedic and cardiovascular products at different levels. Coronary stents, pacemakers, heart valve prostheses and implantable defibrillators are Class IV because of direct contact with the heart or the circulatory system; orthopedic implants, intraocular lenses and hernia repair meshes are mostly Class III. Both are implants, but their filing pathways and review depth are entirely different, so the contact-site analysis should be completed before any project planning is committed.

Insight three: implantables carry an additional traceability obligation on top of classification. Resolución M.S. 2175/2013 applies first-phase traceability management to eight categories of implantable devices, including cardiac defibrillators and cardioverters, cochlear auditory stimulators, intraocular lenses, pacemakers, internal breast prostheses, coronary vascular stents, hip joint prostheses and spinal prostheses. Classification is therefore not only a review question — for listed products it also triggers separate traceability duties that must be budgeted for in the launch plan.

4. Practical recommendations

1. First settle the official formulation of the residence time. Use the same duration formulation in the classification justification and the instructions for use, and retain the clinical basis supporting it.
2. Determine up- or down-classing by contact site. Check one by one whether the device contacts the heart, the circulatory system or the central nervous system, and whether it produces a biological effect or is mostly absorbed, and confirm on that basis whether Class IV applies.
3. Start traceability preparation in parallel for implantables. If the product falls within the eight-category list of Resolución 2175/2013, apply for GS1 GLN codes early and plan the data carrier on the outer packaging.
4. Reserve full clinical evidence time for Class IV products. Class III and IV follow the regular registration pathway, and where the technical report is insufficient to demonstrate safety and effectiveness, ANMAT will require clinical studies — so evidence preparation must be brought forward.

The practical consequence of this layering is that the traceability check should be run at the same time as the classification analysis, not after it. The eight-category list is fixed and public, so a five-minute comparison of the product against the list — defibrillators and cardioverters, cochlear auditory stimulators, intraocular lenses, pacemakers, internal breast prostheses, coronary stents, hip prostheses and spinal prostheses — tells the project team immediately whether a second compliance stream must be funded alongside the registration itself.

5. Verification checklist

• □ Implant status and residence time (whether more than 30 days) confirmed under Rule 8
• □ Applicability of the three up- and down-classing exceptions checked one by one
• □ The classification conclusion (Class II / III / IV) recorded in a written justification report
• □ Checked whether the product is within the eight-category list of Resolución 2175/2013
• □ GS1 coding and traceability system preparation started for listed products
• □ Clinical evidence preparation plan scheduled for Class IV products

Regulatory information verified as of October 29, 2026.

In Argentina, GRZAN operates a wholly owned subsidiary that can act as the registration holder and importer for foreign manufacturers, directly undertaking classification determination, pathway selection, GMP and CFS documentation chains, Spanish-language localization of technical documentation and labels, HELENA submissions and deficiency responses, as well as BONITA import notifications, operation of the ARGOS vigilance system, change maintenance and 5-year renewal planning.

The GRZAN regulatory team consists of professionals with many years of hands-on international registration experience and continuously tracks the developments of regulatory authorities worldwide; all published content follows the editorial standard of conclusions first, traceable bases and verifiable figures. For a tailored market access plan for Argentina or the MERCOSUR region covering a specific product, contact the GRZAN regulatory team at info@grzanglobal.com.